WA
BMRN icon

Winfield Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Winfield Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-150
Closed -$14K – 182
2017
Q4 		$14K Sell
150
-65
-30% -$5.65K 0.01% 373
2017
Q3 		$20K Sell
215
-29
-12% -$2.56K 0.01% 289
2017
Q2 		$22K Buy
244
+47
+24% +$4.28K 0.01% 274
2017
Q1 		$17K Buy
+197
New +$17.5K 0.01% 287

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Winfield Associates's BMRN Position: Q1 2018 in Review

Winfield Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2018, closing a stake of 150 shares — an estimated $14K sold.

Winfield Associates first reported a position in BMRN in Q1 2017 and held it in 4 quarters. The position peaked at $22K in Q2 2017. 429 funds tracked by Wall St. Rank hold BMRN as of Q1 2018.

  • Winfield Associates reported no remaining BioMarin Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 150 BioMarin Pharmaceuticals shares in Q1 2018, an estimated $14K.
  • Winfield Associates first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Winfield Associates's BioMarin Pharmaceuticals position peaked at $22K in Q2 2017.
  • 429 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.